Loading
Exai Bio's study of tumour-specific small RNAs in blood for detecting colorectal cancer.
In the independent validation set of 192, overall sensitivity was 89 per cent at 90 per cent specificity, with 80 per cent sensitivity for stage I.
Cell-free orphan RNAs detect early colorectal cancer in a case-control setting.
Shares Exai Bio, Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Exai Bio, Liquid RNA biopsy (cell-free, vesicle and platelet RNA).
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Shares Liquid RNA biopsy (cell-free, vesicle and platelet RNA), Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/